Kenneth Hoberman

Kenneth Hoberman

Chief Operating Officer at STEMLINE THERAPEUTICS, INC.

Net worth: 12 M $ as of 30/05/2026

61 year
Health Technology
Consumer Services

Profile

Kenneth Hoberman is Vice Chairman at Lirum Therapeutics, Inc. since 2021.
Mr. Hoberman is Independent Director at TG Therapeutics, Inc. since 2014.
Mr. Hoberman is Independent Director at Nuvectis Pharma, Inc. since 2021.
Mr. Hoberman is Chief Operating Officer at Stemline Therapeutics, Inc. since 2013.
Mr. Hoberman was Vice President-Corporate & Business Development at Keryx Biopharmaceuticals, Inc. from 2004 to 2012.
Mr. Hoberman completed undergraduate studies at Boston University.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
10/06/2026 279,653 ( 0.18% ) 11 M $ 30/05/2026
10/06/2026 168,140 ( 0.63% ) 2 M $ 30/05/2026

Kenneth Hoberman active positions

CompaniesPositionStart
STEMLINE THERAPEUTICS, INC. Chief Operating Officer 31/12/2012
TG THERAPEUTICS, INC. Director/Board Member 14/12/2014
NUVECTIS PHARMA, INC. Director/Board Member 30/06/2021
LIRUM THERAPEUTICS, INC. Director/Board Member 31/10/2021

Former positions of Kenneth Hoberman

CompaniesPositionEnd
KERYX BIOPHARMACEUTICALS Corporate Officer/Principal 31/12/2011
See the detail of Kenneth Hoberman's experience

Training of Kenneth Hoberman

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

31

1st degree connections

6

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies6

Health Technology

Health Technology

Health Technology

Consumer Services

Health Technology

Health Technology

  1. Stock Market
  2. Insiders
  3. Kenneth Hoberman